Your SlideShare is downloading. ×
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024

257

Published on

Obesity has been described as a 'public health time-bomb'. In 2005, the World Health Organization estimated that approximately 400 million individuals are obese. Prevalence of obesity is rising …

Obesity has been described as a 'public health time-bomb'. In 2005, the World Health Organization estimated that approximately 400 million individuals are obese. Prevalence of obesity is rising worryingly in many countries, despite campaigns emphasizing the link between being overweight and contracting diabetes. This new report - Anti-Obesity Treatments 2009-2024 ' explains those trends in commercial terms. In two of the largest national markets for anti-obesity treatments - the US and UK - over 20% of the population are seriously overweight. Obesity is a major risk factor in a number of other serious disorders, particularly diabetes and heart disease. Importantly, the financial burden of obesity and its associated conditions - both direct and indirect costs - are vast. Obesity is a serious, chronic condition with an emerging market for therapeutic products, as we show in this study. High socioeconomic costs and increasing prevalence are inspiring government initiatives to deal with the problem, with obesity becoming one of the most prominent global health concerns worldwide. The author of this report recognizes the contribution of drugs in this important emerging market, as diet and exercise are frequently not successful alone. We predict that new classes of drugs will invigorate the market - driving total sales in the next decade. In this report you will find out about those treatments, especially their sales potential. Drug sales in the global anti-obesity market approached $2bn in 2008, with the market to grow substantially over the forecast period 2009-2024. This growth will be associated with a complex environment of label changes, reformulations, patent expiry, OTC switching and new product launches. Those opportunities are highlighted by the extensive R&D pipeline, crowded with novel therapies to improve treatment of obesity. Which new treatments have blockbuster potential' Our report will cover this and other important matters. Importantly, too, prevalence of obesity is rising in Latin America, India and China in particular ' important pharmaceutical markets covered here. Anti-Obesity Treatments 2009-2024 provides detailed analysis of the global anti-obesity market, with comprehensive sales forecasting. With a rigorous study of sources, including commercial databases, company reports, industry news and first-hand interviews with experts in the obesity sector, this report is a unique opportunity to discover how your company can develop over the next 5 years. The result is a comprehensive market- and industry-based report with detailed analyses and informed opinion that you will not find anywhere else. Anti-Obesity Treatments 2009-2024 highlights the following essential aspects of the market: ' A global forecast for the anti-obesity drugs market with comprehensive discussions ' Sales forecasts for the current-leading drugs ' Assessment of new drug releases, both therapeutically and commercially ' Sales forecasts for the leading national anti-obesity markets, as well as for emerging national markets ' Discussion of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-obesity drug sector ' Extensive analysis of pipeline developments, including avenues for future research ' Discussion of current un-met and under-met needs in the anti-obesity market, revealing both therapeutic needs and commercial opportunities. Why you should buy this report: ' To receive a comprehensive analysis of the prospects for anti-obesity therapies from 2009-2024, including predicted revenues, growth rates and other key metrics ' To identify key pipeline developments, the most promising therapy classes and potential methods of treatment ' To discover the important drivers and restraints for the global anti-obesity market, including factors affecting leading national markets ' To find out where the global anti-obesity market is heading - both technologically and commercially - from the present onwards. This rep

Published in: Economy & Finance, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
257
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024Published on February 2009 Report SummaryObesity has been described as a public health time-bomb. In 2005, the World Health Organization estimated that approximately 400million individuals are obese. Prevalence of obesity is rising worryingly in many countries, despite campaigns emphasizing the linkbetween being overweight and contracting diabetes. This new report - Anti-Obesity Treatments 2009-2024 explains those trends incommercial terms. In two of the largest national markets for anti-obesity treatments - the US and UK - over 20% of the population areseriously overweight. Obesity is a major risk factor in a number of other serious disorders, particularly diabetes and heart disease.Importantly, the financial burden of obesity and its associated conditions - both direct and indirect costs - are vast. Obesity is aserious, chronic condition with an emerging market for therapeutic products, as we show in this study. High socioeconomic costs andincreasing prevalence are inspiring government initiatives to deal with the problem, with obesity becoming one of the most prominentglobal health concerns worldwide.The author of this report recognizes the contribution of drugs in this important emerging market, as diet and exercise are frequentlynot successful alone. We predict that new classes of drugs will invigorate the market - driving total sales in the next decade. In thisreport you will find out about those treatments, especially their sales potential. Drug sales in the global anti-obesity marketapproached $2bn in 2008, with the market to grow substantially over the forecast period 2009-2024. This growth will be associatedwith a complex environment of label changes, reformulations, patent expiry, OTC switching and new product launches. Thoseopportunities are highlighted by the extensive R&D pipeline, crowded with novel therapies to improve treatment of obesity. Which newtreatments have blockbuster potential Our report will cover this and other important matters. Importantly, too, prevalence of obesity isrising in Latin America, India and China in particular important pharmaceutical markets covered here.Anti-Obesity Treatments 2009-2024 provides detailed analysis of the global anti-obesity market, with comprehensive salesforecasting. With a rigorous study of sources, including commercial databases, company reports, industry news and first-handinterviews with experts in the obesity sector, this report is a unique opportunity to discover how your company can develop over thenext 5 years. The result is a comprehensive market- and industry-based report with detailed analyses and informed opinion that youwill not find anywhere else. Anti-Obesity Treatments 2009-2024 highlights the following essential aspects of the market: A global forecast for the anti-obesity drugs market with comprehensive discussions Sales forecasts for the current-leading drugsAnti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 1/11
  • 2. Find Industry reports, Company profilesReportLinker and Market Statistics Assessment of new drug releases, both therapeutically and commercially Sales forecasts for the leading national anti-obesity markets, as well as for emerging national markets Discussion of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-obesity drug sector Extensive analysis of pipeline developments, including avenues for future research Discussion of current un-met and under-metneeds in the anti-obesity market, revealing both therapeutic needs and commercial opportunities.Why you should buy this report: To receive a comprehensive analysis of the prospects for anti-obesity therapies from 2009-2024, including predicted revenues,growth rates and other key metrics To identify key pipeline developments, the most promising therapy classes and potential methods of treatment To discover the important drivers and restraints for the global anti-obesity market, including factors affecting leading national markets To find out where the global anti-obesity market is heading - both technologically and commercially - from the present onwards.This report is essential reading for anyone in the pharmaceutical and healthcare sector with an interest in obesity and relatedconditions. Purchasing this report will help you to recognise those important market opportunities and understand the possibilitiesthere. Table of ContentTable of Contents1 Executive Summary: Anti-Obesity Treatments 2009-20242 An Introduction to Obesity and Its Treatment2.1 What is Obesity2.1.1 Fat is a Necessary Component of the Body2.1.2 Obesity is a Chronic Disease2.1.3 Body Weight is Dependent upon Several Factors2.2 How is Obesity Measured2.2.1 Weight-for-Height Tables2.2.2 Waist Circumference2.2.3 Body Mass Index (BMI)Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 2/11
  • 3. Find Industry reports, Company profilesReportLinker and Market Statistics2.3 How Serious is the Problem2.3.1 Prevalence2.3.2 Risk Factors of Other Diseases (Co-Morbidities)2.3.3 Economic Costs2.4 Historical Causes and Lifestyle Changes2.4.1 Urbanisation, Modernisation and Economic Development2.4.2 Developed Countries and in Developing Nations2.5 Factors Causing Obesity2.5.1 Lifestyle, Environment and Diet2.5.2 Behaviour2.5.3 Psychological Factors2.5.4 Genetics2.5.5 Antecedent Illnesses and Treatments2.5.6 Other Causes2.6 Treatment of Obesity2.6.1 Lifestyle and Behavioural Changes2.6.2 Unapproved Drugs2.6.3 Alternative Therapies2.6.4 Pharmacotherapy2.6.5 Surgical Options2.6.6 Drugs have a Role in the Treatment of Obesity.2.7 Pharmacotherapy in the Treatment of Obesity2.7.1 Lipase Inhibitors2.7.2 Anorectic Drugs2.7.3 Off-Label Use of Drugs2.8 Need for Future Development in the Treatment of Obesity2.8.1 Unmet Needs and Market Potential3 The World Market for Anti-Obesity Drugs, 2009-20243.1 The Current Anti-Obesity Market Climate - a Potential Blockbuster Market3.2 Leading Companies in the Anti-Obesity Market3.3 Market History and the Current Situation3.3.1 The Effect of Pondimin, Redux and Public Opinion on the Anti-Obesity Market3.3.2 Rimonabant and other Cannabinoid Receptor Antagonists3.3.3 Phentermine3.4 Total Anti-Obesity Market Forecast 2009-20243.4.1 Market Growth in 2009-20243.4.2 Drugs after 20123.5 Xenical Forecast 2009-20243.5.1 Will Generic Erosion Drive Down Xenicals Sales3.5.2 Competition Increases with New Releases3.5.3 Will Xenical be Driven Out by Newer Rivals3.6 Reductil/Meridia Forecast 2009-20243.6.1 How Will Competition Affect Sales3.6.2 Expiry of Patents in 20133.7 Alli Forecast 2009-20243.7.1 Early Launch-Stocking3.7.2 European Launch3.7.3 Is Alli Failing to Distinguish ItselfAnti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 3/11
  • 4. Find Industry reports, Company profilesReportLinker and Market Statistics3.8 Dinintel Forecast 2009-20243.8.1 Will the Rapidly Evolving Anti-Obesity Market Will Leave Dinintel Behind3.9 Total Other Drugs Forecast 2009-20243.9.1 Generic Competitors3.9.2 New Drug: Contrave (Orexigen)3.9.3 New Drug: Lorcaserin (Arena)3.9.4 New Drug: Qnexa (Vivus)3.9.5 New Drug: Liraglutide (Novo Nordisk)3.9.6 New Drug: Empatic/Excalia (Orexigen)3.10 Market Summary3.10.1 New Drugs and the Market3.10.2 Lack of Innovation and the Market Opportunities3.10.3 The Problems with Anorectic Drugs3.10.4 The Problems with Lipase Inhibitors3.10.5 The Future of Anti-Obesity Treatments4 Anti-Obesity Treatments - SWOT Analysis4.1 Strengths4.1.1 Long-Term Therapy with Anti-Obesity Drugs4.1.2 Prospects of Multiple Indications for Anti-Obesity Drugs4.1.3 Off-Label Potential and Competition4.1.4 The Anti-Obesity Market is Ready to be Revolutionised4.1.5 Failure of Rimonabant Leaves Vacuum in the Market4.1.6 New Drugs May Not Fill the Entirety of Customer Needs4.2 Weaknesses4.2.1 Limited Efficacy4.2.2 Undesirable Side-Effects Limit Market Potential of Anti-Obesity Medications4.2.3 Increased Competition by both Impending New Releases and Generic Competitors4.2.4 Regulatory Hurdles have Become Stricter - Companies Pay the Price4.2.5 Pharmacotherapy Will Never be the First Line of Treatment4.3 Opportunities4.3.1 Rising Prevalence Drives Market Potential4.3.2 Unmet Market Needs - Can Drugs Solve this Problem4.3.3 A Safe and Effective Anti-Obesity Treatment has Applications in Both the Clinical and Cosmetic Sectors4.3.4 How the Changing Government Agenda and the High Economic Costs of Obesity Will Drive Growth in the Anti-Obesity Market4.3.5 Diet and Exercise May be the Mainstay Treatment, but this Approach is not Always Effective4.4 Threats4.4.1 Reimbursement May Continue to be a Limiting Factor4.4.2 Long-Term Safety Issues Continue to Stunt Growth4.4.3 Opinion of Both the Public and Prescribing Bodies is Heavily Dependent upon Individual Drug Successes and Success of theMarket as a Whole4.4.4 Will Healthier Lifestyles Limit the Current Need for Anti-Obesity Drugs5 Pipeline Developments in Anti-Obesity Treatments5.1 Treatments in Phase III5.1.1 Lorcaserin5.1.2 Qnexa5.1.3 ContraveAnti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 4/11
  • 5. Find Industry reports, Company profilesReportLinker and Market Statistics5.1.4 Cetilistat5.2 Treatments in Phase II5.2.1 Empatic/Excalia5.2.2 Liraglutide5.2.3 Obinepitide5.2.4 Solabegron5.2.5 Tesofensine5.2.6 Velneperit5.2.7 Histalean5.2.8 Sodium Tungstate5.2.9 Serglifozin Etabonate5.2.10 Pramlintide & Metreleptin5.2.11 Hoodia gordonii Extract5.2.12 MTP Inhibitor5.2.13 TM 303395.2.14 SLx 40905.2.15 MK 04935.2.16 KRP 2045.2.17 FM VP45.2.18 AZD 22075.2.19 CE 3265975.3 Treatments in Phase I5.3.1 Trodusquemine5.3.2 THCV5.3.3 Oral PYY3-365.3.4 ATHX 1055.3.5 AZD 11755.3.6 AZD 16565.3.7 BVT 743165.3.8 CP 4045.3.9 KD 30105.3.10 PRX 070345.3.11 PSN 6025.3.12 TKS 12255.3.13 V 243435.3.14 TTP 4355.4 Other Promising Pipeline Developments5.4.1 Melanotan5.4.2 Increasing Mitochondrial Activity to Increase Energy Expenditure5.4.3 Inhibiting the Creation of Fat Stores after Gut Absorption6 Obesity in the Leading World Markets6.1 The Total Market for Anti-Obesity Treatments6.1.1 Drug Development Will Drive the Market6.2 US Anti-Obesity Market Forecast 2009-20246.2.1 Patent Expiries and New Drug Releases Will Create a Turbulent Market6.2.2 Will The Market Show Uninhibited Growth During the Forecast Period6.3 Mexico Anti-Obesity Market Forecast 2009-20246.3.1 The Health Care System Currently Limits Treatment AccessibilityAnti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 5/11
  • 6. Find Industry reports, Company profilesReportLinker and Market Statistics6.3.2 Prevalence of Obesity Driving the Market6.4 Brazil Anti-Obesity Market Forecast 2009-20246.4.1 Increasing Prevalence Will Force an Increase in Sales over the Forecast Period6.5 UK Anti-Obesity Market Forecast 2009-20246.5.1 Lagging Sales Will Turn to Positive Growth in the Early Forecast Period6.5.2 Government Agenda Will Support Growth of Anti-Obesity Treatments in the UK6.6 South Korea Anti-Obesity Market Forecast 2009-20246.6.1 Government Agenda Will Maintain High Sales6.7 Spain Anti-Obesity Market Forecast 2009-20246.7.1 New Drug Releases and Patent Expiries6.7.2 The Market Will Show Consistent Positive Growth6.8 France Anti-Obesity Market Forecast 2009-20246.8.1 Reimbursement will Drive Sales6.9 Total Other Countries Anti-Obesity Market Forecast 2009-20246.9.1 Total Other Countries Sales6.9.2 The Impact of Emerging Markets6.9.3 Emerging Market: India6.9.4 Emerging Market: China7 Experts Views on the Main Issues in the Treatment of Obesity7.1 An Interview with Dr. Tyrberg from The Burnham Institute Diabetes and Obesity Research Centre7.1.1 The Effect of Anti-Obesity Drugs on the Obese Population7.1.2 The Cause-Effect Relationship between Diet, Obesity and Type 2 Diabetes7.1.3 Off-Label Indications and Diabetes Treatments Used to Treat Obesity7.1.4 Obesity as a Lifestyle Disease7.1.5 The Future of Anti-Obesity Treatments and the Role Diet and Exercise Will Play7.1.6 The Role of Pharmaceutical Companies, Ethics and the Cosmetic Use of Anti-Obesity Treatments7.1.7 Unmet Medical Needs in the Treatment of Obesity7.1.8 The Future of the Anti-Obesity Market7.2 Commentaries and Views from Other Experts in the Field7.2.1 The Most Important Unmet Medical Needs in the Treatment of Obesity7.2.2 The Future of Anti-Obesity Treatment7.2.3 Funding of Anti-Obesity Treatments7.2.4 The Anti-Obesity Market in Developing Nations7.2.5 Concluding Thoughts8 Conclusions8.1 Obesity is a Chronic Disease with Serious Health Implications8.2 The Prevalence and Economic Costs of Obesity8.3 The Modern Lifestyle has Contributed Significantly to Obesity8.4 Obesity is Caused by a Complex Interplay of Factors8.5 Obesity Treatments and the Role of Pharmaceuticals8.6 The Unmet Needs and Market Potential for Anti-Obesity Treatments8.7 The Anti-Obesity Market Will Expand from 2009-20248.8 The Main Drivers and Restraints of the Anti-Obesity Market8.9 Geographical Overview of the Anti-Obesity Market8.10 Outlook for the FutureAnti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 6/11
  • 7. Find Industry reports, Company profilesReportLinker and Market StatisticsAppendicesAppendix 1: Conditions Associated with ObesityAppendix 2: Bariatric Surgery OptionsAppendix 3: About the authorAppendix 4: Evaluation FormList of TablesTable 2.1 - BMI Classification BandsTable 2.2 - Obesity Prevalence Amongst US Adults 1991-2007Table 3.1 - Leading Anti-Obesity Drugs in Sales ($m), Market Share (%) and Growth (%), 2007Table 3.2 - Leading Companies for Anti-Obesity Drugs in Sales ($m) and Market Share (%), 2007Table 3.3 -Total Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 3.4 - Total Anti-Obesity Market CAGR Values (%), 2009-2024Table 3.5 - Xenical Forecast in Sales ($m) and Growth (%), 2009-2024Table 3.6 - Xenical CAGR Values (%), 2009-2024Table 3.7 - Reductil/Meridia Forecast in Sales ($m) and Growth (%), 2009-2024Table 3.8 - Reductil/Meridia CAGR Values (%), 2009-2024Table 3.9 - Alli Forecast in Sales ($m) and Growth (%), 2009-2024Table 3.10 - Alli CAGR Values (%), 2009-2024Table 3.11 - Dinintel Forecast in Sales ($m) and Growth (%), 2009-2024Table 3.12 - Dinintel CAGR Values (%), 2009-2024Table 3.13 - Total Other Drugs Forecast in Sales ($m) and Growth (%), 2009-2024Table 3.14 - Total Others Drugs CAGR Values (%), 2009-2024Table 4.1 - SWOT Chart of the Anti-Obesity Market, 2009-2024Table 5.1 -The Anti-Obesity Pipeline 2009Table 6.1 - US Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 6.2 - US Anti-Obesity Market CAGR Values (%), 2009-2024Table 6.3 - Mexico Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 6.4 - Mexico Anti-Obesity Market CAGR Values (%), 2009-2024Table 6.5 - Brazil Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 6.6 - Brazil Anti-Obesity Market CAGR Values (%), 2009-2024Table 6.7 - UK Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 6.8 - UK Anti-Obesity Market CAGR Values (%), 2009-2024Table 6.9 - South Korea Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 6.10 - South Korea Anti-Obesity Market CAGR Values (%), 2009-2024Table 6.11 - Spain Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 6.12 - Spain Anti-Obesity Market CAGR Values (%), 2009-2024Table 6.13 - France Anti-Obesity Market CAGR Values (%), 2009-2024Table 6.14 - France Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 6.15 - Total Other Countries Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024Table 6.16 - Total Other Countries Anti-Obesity Market CAGR Values (%), 2009-2024Table A2.1 - Bariatric Surgery OptionsList of FiguresFigure 2.1 - Obesity Prevalence Amongst US Adults 1991-2007Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 7/11
  • 8. Find Industry reports, Company profilesReportLinker and Market StatisticsFigure 3.1 - Leading Anti-Obesity Drugs Sales ($m), 2007Figure 3.2 - Leading Anti-Obesity Drugs Market Share (%), 2007Figure 3.3 - Leading Companies of Anti-Obesity Drugs Sales ($m), 2007Figure 3.4 - Leading Companies Anti-Obesity Market Share (%), 2007Figure 3.5 - Total Anti-Obesity Market Sales ($m), 2009-2024Figure 3.6 - Xenical Sales ($m), 2009-2024Figure 3.7 - Reductil/Meridia Sales ($m), 2009-2024Figure 3.8 - Alli Sales ($m), 2009-2024Figure 3.9 - Dinintel Sales ($m), 2009-2024Figure 3.10 - Total Other Drugs Sales ($m), 2009-2024Figure 3.11 - All Drugs Market Share (%), 2009-2024Figure 6.1 - Total Anti-Obesity Market Sales ($m), 2009-2024Figure 6.2 - US Anti-Obesity Market Forecast Sales ($m), 2009-2024Figure 6.3 - Mexico Anti-Obesity Market Forecast Sales ($m), 2009-2024Figure 6.4 - Brazil Anti-Obesity Market Forecast Sales ($m), 2009-2024Figure 6.5 - UK Anti-Obesity Market Forecast Sales ($m), 2009-2024Figure 6.6 - South Korea Anti-Obesity Market Forecast Sales ($m), 2009-2024Figure 6.7 - Spain Anti-Obesity Market Forecast Sales ($m), 2009-2024Figure 6.8 - France Anti-Obesity Market Forecast Sales ($m), 2009-2024Figure 6.9 - Total Other Countries Anti-Obesity Market Forecast Sales ($m), 2009-2024Figure 6.10 - Anti-Obesity Combined Country Forecast Sales ($m), 2009-2024Figure 6.11 - Anti-Obesity Market Country Market Share Forecast (%), 2009-2024Figure 8.1 - Total Anti-Obesity Market Sales ($m), 2009-2024Figure 8.2 - Anti-Obesity Drugs Forecast by Market Share (%), 2009-2024Figure 8.3 - Anti-Obesity Combined Country Forecast Sales ($m), 2009-2024Figure 8.4 - Anti-Obesity Market Country Market Share Forecast, 2009-2024Companies Listed7TM PharmaAbbottAche LaboratoriesActavisAlizymeAmerican Home ProductsAmylinArenaAstraZenecaAthersysBarcelona UniversityBayerBiovitrumBristol-Myers SquibbClinuvelCompellisCouncil for Scientific and Industrial ResearchDuke UniversityEli LillyEMEAEmisphereAnti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 8/11
  • 9. Find Industry reports, Company profilesReportLinker and Market StatisticsEMSEpixFDAForbes Medi-TechGate PharmaceuticalsGenaeraGlaxoSmithKlineGraceway PharmaGW PharmaceuticalsHan WhaHanmiInova PharmaJohnson & JohnsonKalypsysKisseiKyorinLouisiana State UniversityMedleyMerck & Co.NeuroSearchNovartisNovo NordiskNycomed PharmaOBEcureOrexigenOSI PharmaceuticalsPfizerPhytopharmRocheSanofi-AventisShionogiSirtris PharmaceuticalsSolvaySurface LogixTakedaTevaThe Burnham InstituteTransitionTransTechURL PharmaVernalisVivusWyeth PharmaceuticalsAnti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 9/11
  • 10. Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 417.21 Quantity: _____ Department License--USD 4 834.42 Quantity: _____ Site License--USD 8 046.71 Quantity: _____ Corporate License--USD 11 265.95 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 10/11
  • 11. Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024 Page 11/11

×